Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Tam

Showing results (881-890 of 922) with videos related to

Pageof 93
Sort By:
Blood Advances|May 5, 2026
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphomaJoseph P McGuirk, Armin Ghobadi, Carlos R Bachier, et al.
Internal Medicine Journal|May 17, 2020
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemicPietro Di Ciaccio, Georgia McCaughan, Judith Trotman, et al.
Blood|April 16, 2025
International Consensus Statement on Diagnosis, Evaluation, and Research of Richter Transformation: the ERIC RecommendationsAdam S Kittai, Monia Marchetti, Othman Al-Sawaf, et al.
Blood Advances|December 7, 2020
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trialMeletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2024
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIAMazyar Shadman, Talha Munir, Tadeusz Robak, et al.
Internal Medicine Journal|May 28, 2021
COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statementGeorgia McCaughan, Pietro Di Ciaccio, Michelle Ananda-Rajah, et al.
Frontiers in Immunology|March 23, 2023
Immunogenicity against wild-type and Omicron SARS-CoV-2 after a third dose of inactivated COVID-19 vaccine in healthy adolescentsDaniel Leung, Carolyn A Cohen, Xiaofeng Mu, et al.
Blood|July 31, 2020
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN studyConstantine S Tam, Stephen Opat, Shirley D'Sa, et al.
Blood Advances|January 25, 2023
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinibSilvia Bonfiglio, Lesley-Ann Sutton, Viktor Ljungström, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2025
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell LymphomaRichard T Maziarz, Michael R Bishop, Constantine S Tam, et al.
Pageof 93

Showing results (881-890 of 922) with videos related to

Sort By:
Pageof 93
Blood Advances|May 5, 2026
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphomaJoseph P McGuirk, Armin Ghobadi, Carlos R Bachier, et al.
Internal Medicine Journal|May 17, 2020
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemicPietro Di Ciaccio, Georgia McCaughan, Judith Trotman, et al.
Blood|April 16, 2025
International Consensus Statement on Diagnosis, Evaluation, and Research of Richter Transformation: the ERIC RecommendationsAdam S Kittai, Monia Marchetti, Othman Al-Sawaf, et al.
Blood Advances|December 7, 2020
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trialMeletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2024
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIAMazyar Shadman, Talha Munir, Tadeusz Robak, et al.
Internal Medicine Journal|May 28, 2021
COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statementGeorgia McCaughan, Pietro Di Ciaccio, Michelle Ananda-Rajah, et al.
Frontiers in Immunology|March 23, 2023
Immunogenicity against wild-type and Omicron SARS-CoV-2 after a third dose of inactivated COVID-19 vaccine in healthy adolescentsDaniel Leung, Carolyn A Cohen, Xiaofeng Mu, et al.
Blood|July 31, 2020
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN studyConstantine S Tam, Stephen Opat, Shirley D'Sa, et al.
Blood Advances|January 25, 2023
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinibSilvia Bonfiglio, Lesley-Ann Sutton, Viktor Ljungström, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2025
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell LymphomaRichard T Maziarz, Michael R Bishop, Constantine S Tam, et al.
Pageof 93